Note 6 - Other Intangible Assets |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Goodwill and Intangible Assets Disclosure [Abstract] | |
| Other Intangible Assets | 6. Other Intangible Assets The net carrying value of the Company’s in-process research and development (IPR&D) assets was $40 million at each of March 31, 2026 and December 31, 2025. The Company’s IPR&D assets represent the estimated fair value of its pipeline of acquired radiotherapy program candidates. The Company tests its indefinite-lived intangible assets for impairment during the fourth quarter of each year, or more frequently should circumstances change or events occur that would more likely than not reduce the fair value of its assets. No testing was deemed necessary during the three months ended March 31, 2026. For additional information related to the Company’s IPR&D assets, see Notes 2 and 9 in the Company’s 2025 Form 10-K. |